Abivax Shares Climb 2.77% at Close Amid New Acquisition Rumors
Abivax shares increased by 2.77% on Tuesday, January 20, closing at 103.80 euros, amid fresh speculation about a potential merger and acquisition operation. According to reports by La Lettre, British pharmaceutical group AstraZeneca is said to have proposed about 176 euros per share by the end of 2025. This renewed interest in the French biotechnology company comes a few weeks after its inclusion in the Nasdaq Biotechnology Index, effective since December 22, 2025.
Market Analysts Link Share Price Increase to Media Reports on Mergers and Acquisitions
Analysts from Kepler Cheuvreux and ODDO BHF attribute the rise in the typically volatile stock to a new media report fueling discussions on mergers and acquisitions. The biotech has recently been the subject of increasing merger and acquisition talks, especially after a report mentioned a 15 billion euro offer from Eli Lilly. However, the French Ministry of Finance stated that it had not received any formal request for investment approval. Regarding analyst recommendations, two analyst offices have recently revised their price targets upwards. Stifel raised its target from 100 to 142 euros on January 15 with a buy recommendation, while Kepler Cheuvreux moved it from 70 to 130 euros on January 13. These targets suggest a potential appreciation of 36.87% and 25.24% respectively from the closing price on January 20. Since the beginning of the year, ABIVAX has shown a 1,619% increase over twelve months and 32.23% over three months, while losing 0.19% over the last seven days.
Technical Analysis of ABIVAX Shows a Mixed Profile
The technical analysis of ABIVAX reveals a mixed profile. The stock is currently close to its 50-day moving average (103.55 euros), a key level that acts as dynamic support, but is in a neutral zone. The RSI is at 32, indicating a beginning of fatigue without yet reaching the oversold zone, while the monthly volatility of 25.06 reflects the significant amplitude of daily fluctuations, characteristic of a stock subject to strong speculation. In terms of graphical levels, the support is at 93.30 euros, while the major resistance is positioned at 122.40 euros. A clear break through this latter level could pave the way for a return to recent highs. The 200-day moving average, established at 55.05 euros, illustrates the extent of the stock market rally achieved in 2025. In the short term, the stock's performance will depend on the confirmation or refutation of acquisition rumors, as well as the publication of the results of the phase 3 maintenance trial expected in the second quarter of 2026.
